0001415889-25-004457.txt : 20250218 0001415889-25-004457.hdr.sgml : 20250218 20250218170011 ACCESSION NUMBER: 0001415889-25-004457 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250213 FILED AS OF DATE: 20250218 DATE AS OF CHANGE: 20250218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Donoghoe Nicholas CENTRAL INDEX KEY: 0001762951 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 25635949 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 4 1 form4-02182025_050205.xml X0508 4 2025-02-13 0001551152 AbbVie Inc. ABBV 0001762951 Donoghoe Nicholas 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 false true false false EVP, CHIEF BUS/STRAT OFFICER 0 Common Stock, $0.01 par value 2025-02-13 4 A 0 11017 0 A 66920 D Common Stock, $0.01 par value 2025-02-13 4 A 0 4520 0 A 71440 D Common Stock, $0.01 par value 2025-02-13 4 A 0 4634 0 A 76074 D Common Stock, $0.01 par value 2025-02-13 4 A 0 5174 0 A 81248 D Option (Right to buy) 192.86 2025-02-13 4 A 0 23437 0 A 2035-02-12 Common Stock 23437 23437 D Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,813 on February 13, 2026, 7,812 on February 13, 2027, and 7,812 on February 13, 2028. Due to an administrative error the exercise price for options awarded February 15, 2024 was previously reported as $0 in Table II Column 2, instead of the correct value of $175.28 /s/ T.O. Odutayo, Attorney-in-Fact for Nicholas J. Donoghoe 2025-02-18